Howard Wolinsky takes another step on his active surveillance travels

In his latest post on the MedPage Today web site, Howard Wolinsky (a freelance journalist based in the Chicago area), who has been on active surveillance since 2010, writes about the result of his most recent rebiopsy. His last one was in 2013. There was (again) “no evidence of malignancy” in the post-biopsy pathology report. … READ MORE …

It was true 3 years ago, but is it still the case?

One of the problems with a lot of research is that it is out of date by the time it is published. The following example may be a classic case in point. And it has serious implications. … READ MORE …

PRIAS reports data from a 5,000+ patient active surveillance study

Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …

Can a man be too young for active surveillance?

There is a “conventional wisdom” that active surveillance (AS) is only for older men, and that younger men are better off having immediate radical treatment, typically prostatectomy (RP).

Management of incident prostate cancer on active surveillance

Back in the dim and distant past (i.e., the 1980s and the very early 1990s, before PSA testing was widespread) one of the most common ways to find early stage prostate cancer was as an incidental consequence of the conduct of a transurethral resection of the prostate (a “TURP”) to treat symptoms of urinary tract obstruction. … READ MORE …

New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …

Expectant management is really “coming of age” in the USA

An excellent new review article in CA: A Cancer Journal of Clinicians, along with a research letter just published in the Journal of the American Medical Association (JAMA) have provided us with an important update on the value and the increasing acceptance of expectant management in the treatment of lower-risk forms of prostate cancer. … READ MORE …